Author: Customer Service

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”). The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the “Consideration Shares”). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation period of 3 years from January 2026 to December 2028. Performance Targets January 1, 2026 – December 31, 2026:The target company shall achieve audited...

Tallinna Vesi provides clarification regarding information published in the media about the incident that occurred on 31 December 2025 in the company’s operations. The company has promptly commented on the situation publicly and confirms that the incident was timelimited and its impact on services was shortterm.  On the evening of 31 December 2025, Tallinn’s water supply was affected by an incident caused by an exceptional combination of weather conditions. Frazil ice that formed on Lake Ülemiste repeatedly created an ice barrier in front of the intake pipe, interrupting the flow of water to the treatment plant. As water consumption is higher than usual during New Year’s Eve, the water reserves available at the treatment plant decreased rapidly.   As a result of the incident, water pressure dropped in several districts of the city, particularly...

Geneva, Switzerland, Jan. 09, 2026 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, and a subsidiary of WISeKey International Holding AG (Nasdaq: WKEY; SIX: WIHN) (“WISeKey”), today announced that it has reached a final, binding agreement with Kaynes SemiCon to establish SEALKAYNESQ Ltd, a Joint Venture (“JV”) in India. The JV is being formed with the objective of developing, personalizing, and deploying a Sovereign Indian Post-Quantum semiconductor platform, fully aligned with India’s national digital sovereignty and security priorities, and developed in direct dialogue with India’s Ministry of Electronics and Information Technology (MeitY), the central...

MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (TSXV CDPR) (OTCQB GPPRF) (FRA N8HP) (the Company or CDPR) is pleased to provide an operational review and corporate update highlighting key workstreams completed and consolidated at the Quiulacocha Tailings Project, as the Company transitions toward the next stage of project execution. This update builds on the technical and permitting progress outlined in the Company’s December 10, 2025 news release and reflects the completion and integration of several core Phase 1 programs. Project Positioning Update Over the course of 2025, the Company completed and consolidated the principal technical, environmental and regulatory workstreams required to materially advance the readiness of the Quiulacocha Project. Collectively, this work has reduced execution risk within...

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company has submitted a protocol amendment to the U.S. Food & Drug Administration (“FDA”) for its Phase 3 VERSATILE-003 clinical trial. The proposed amendment to the VERSATILE-003 Phase 3 trial changes the PFS endpoint to a primary endpoint that can be evaluated earlier with significant statistical power, potentially providing the basis for accelerated approval of PDS0101. Median overall survival (mOS) remains...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported data from the Company’s ongoing clinical evaluation and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related...